13.03.2024 - Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced online publication of the BLUE-C study results in The New England Journal of Medicine. The peer-reviewed study, Next-Generation . Seite 1
Cologuard Plus is only noninvasive test to be evaluated head-to-head against an independent fecal immunochemical test, which it significantly outperformed
20,000-participant BLUE-C study included.
The new test detected 94% of cancers and was 91% accurate in determining who didn’t have cancer, up from 92% cancer sensitivity and 87% specificity for the original Cologuard.